Pancreatic cancer is a devastating disease that is often difficult to treat. Traditional treatment options, such as chemotherapy and radiation therapy, have limited success in treating this disease. However, in recent years, immunotherapy has emerged as a promising treatment option
Durvalumab is an immunotherapy drug that is used to treat certain types of cancer. It belongs to a class of drugs called checkpoint inhibitors, which work by releasing the brakes on the immune system, allowing it to attack cancer cells.
Alliance A021806 is a Phase III trial that aims to evaluate the efficacy of perioperative chemotherapy with mFOLFIRINOX in patients with resectable pancreatic cancer.1, 2 The study is actively accruing randomized controlled phase III trial evaluating the efficacy of perioperative chemotherapy with mFOLFIRINOX
The Alliance for Clinical Trials in Oncology, commonly referred to as simply the Alliance, is a cooperative group of researchers and healthcare professionals dedicated to improving the treatment and outcomes for patients with cancer. The Alliance conducts clinical trials to
There are several cooperative cancer groups in the United States, which are collaborative organizations that bring together researchers and institutions to conduct clinical trials and advance cancer research. These groups have played a critical role in advancing cancer care and